The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | A pooled European analysis on the utility of circulating tumor cells for staging multiple myeloma
Luca Bertamini, MD, Erasmus MC, Rotterdam, Netherlands, discusses a pooled European analysis of 2,446 newly diagnosed patients, focused on the utility of circulating tumor cells for staging multiple myeloma. Dr Bertamini highlights the prognostic value of circulating tumor cells at diagnosis. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Here at EHA in Milan 2025 we presented the first results of a large consortium analysis where we pooled data from many different countries and centers and data on this very important biomarker which is circulating tumor cells so myeloma cells in the blood. And we really have the opportunity to put together more than 2,400 patients’ data and really look at the prognostic impact of this biomarker at diagnosis in a really large dataset also correcting for a lot of confounders, other factors, risk factors, treatment, age and the main finding is that this biomarker is really strong, is independent and we can really stratify patients better using it...
Here at EHA in Milan 2025 we presented the first results of a large consortium analysis where we pooled data from many different countries and centers and data on this very important biomarker which is circulating tumor cells so myeloma cells in the blood. And we really have the opportunity to put together more than 2,400 patients’ data and really look at the prognostic impact of this biomarker at diagnosis in a really large dataset also correcting for a lot of confounders, other factors, risk factors, treatment, age and the main finding is that this biomarker is really strong, is independent and we can really stratify patients better using it.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
